Mutabilis
  • About us
    • Company overview
    • Management
    • Scientific Advisory Board
    • Partners
  • R&D
    • Pipeline
  • News
  • Contact
    • Localization

  • Home
  • Blog
  • All
  • News

Mutabilis presents EBL-1463 at the 2020 online AMR Conference.

By: admutabilis | Tags: | Comments: 0

September 2020. Due to the Covid-19 restrictions the 2020 AMR conference had to be held on the Internet this year. Within the session dedicated to the presentation of the IMI-ENABLE’s results, François Moreau, Mutabilis’ CSO, gave a presentation on EBL-1463. The presentation can be viewed here.

READ MORE

Novo Holdings REPAIR invests in Mutabilis

By: admutabilis | Tags: | Comments: 0

January 6th 2020: Novo Holdings REPAIR Impact fund announced a EUR 7 (USD 8) million investment in Mutabilis to accelerate its 2G Dabocins program

READ MORE

Mutabilis will present at “Superbugs & Superdrugs”. 30-31 March 2020. London, UK.

By: admutabilis | Tags: | Comments: 0

Title of the talk : DISCOVERY OF DABOCINS, A NOVEL CLASS OF NON-BETA-LACTAM PBP INHIBITORS

READ MORE

ENABLE (IMI) selects one of Mutabilis’ programme as new antibiotic candidate. Nov 6th 2019

By: admutabilis | Tags: | Comments: 0

Following the integration of Mutabilis’ second programme in ENABLE in April 2018, the ENABLE Portfolio Management Committee has selected a candidate from this programme.

READ MORE

Mutabilis at the next ASM MICROBE conference held in San-Francisco from June 20th to 24th 2019

By: admutabilis | Tags: | Comments: 0

Mutabilis will be represented at the ASM MICROBE 2019 conference in San-Francisco from June 20th to 24th 2019.

READ MORE

Mutabilis at the 12th Berlin Conference on Novel Antimicrobials 2019

By: admutabilis | Tags: | Comments: 0

Like last year, Mutabilis delegates will participate to the Berlin Conference on Novel Antimicrobials and Diagnosstics 2019 on March 14th – 15th 2019.

READ MORE

The World Health Organization releases a report on the clinical pipeline of antibiotics

By: admutabilis | Tags: | Comments: 0

The World Health Organization had published earlier this year a list of the most concerning pathogens. The WHO continues with a report on the pipeline of antibiotics currently in clinical development to assess how we are going to manage the pathogens of the list.

READ MORE

Mutabilis joins the European ENABLE consortium to fight antibiotic resistance (october 17th 2017).

By: admutabilis | Tags: | Comments: 0

Mutabilis has been selected by the European ENABLE project (European Gram-negative Antibacterial Engine), which aims to improve the development of antibiotics against infections caused by multiresistant Gram-negative bacteria.

READ MORE

DRIVE-AB final conference : New economic models for much needed innovative antibiotics presented at the (5-6 september 2017, Brussels). (June 1st 2017)

By: admutabilis | Tags: | Comments: 0

The DRIVE-AB project is part of the IMI’s New Drug For Bad Bugs (ND4BB) initiative

READ MORE

The European Commission has released a new action plan against Antimicrobial Resistance (AMR). (May 5th 2017)

By: admutabilis | Tags: | Comments: 0

The new European AMR plan relies on the “One Health” approach

READ MORE
  • 1
  • 2
  • 3
  • Next »

MUTABILIS


Biocitech Park, 102 avenue Gaston Roussel, 93230 Romainville, France info@mutabilis.fr


Mutabilis is a biopharmaceutical company specialized in research and development of anti-infectious treatments.


Legal notice / Contact us